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 The late physician-scientist Dr Judah 
Folkman, considered by many to be the 
father of antiangiogenic cancer therapies, 
showed that certain types of experimental 
cancers in mice could be cured by disrupt-
ing their blood supply without directly 
attacking the tumor cells. His revolution-
ary treatment is currently being tested 
in patients with angiogenic tumors, includ-
ing AIDS-associated Kaposi ’ s sarcoma. 
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 Can we cure HIV-1-associated 
nephropathy in transgenic mice ? 
 Patricio E.  Ray 1 , 2 
 HIV-1 – associated nephropathy (HIVAN) is a rapidly progressive form 
of focal segmental glomerulosclerosis. HIV transgenic mice can 
develop a HIVAN-like renal disease. Zhong  et al. show that the oral 
administration of a cyclic nucleotide phosphodiesterase 4 inhibitor 
and a retinoic acid receptor-  agonist can prevent the development 
of HIVAN in transgenic mice, acting through a cAMP-dependent 
mechanism that is independent of HIV-1 genes. These findings suggest 
that endogenous host factors play a critical role in HIVAN. 
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different from that of AIDS-associated 
Kaposi ’ s sarcoma, HIVAN is characterized 
by the excessive proliferation of renal 
glomerular and tubular epithelial cells, 
leading to the microcystic transformation 
of renal tubules and rapid development of 
focal segmental glomerulo sclerosis. Th ere-
fore, the new study by Zhong  et al. 1 (this 
issue) challenges us to ask a similar type of 
question: Can we cure HIVAN in trans-
genic (Tg) mice without attacking the 
HIV-1 genes? 
 Briefl y, the study by Zhong  et al. 1 shows 
that the oral administration of two drugs 
that increase the intracellular levels of 
cyclic adenosine monophosphate (cAMP), 
rofl umilast and Am580, is capable of cur-
ing HIVAN in Tg mice without aff ecting 
the expression of HIV-1 genes. Rofl umi-
last is a cyclic nucleotide phosphodieste-
rase 4 (PDE4) inhibitor that increases 
the intracellular concentration of cAMP 
by blocking its degradation. Am580 is a 
specifi c retinoic acid receptor-  (RAR  ) 
agonist that has several systemic and renal 
effects, including increasing the intra-
cellular levels of cAMP. Both drugs, acting 
in a synergistic manner, prevented the 
progression of the renal disease in HIV-Tg 
mice by blocking the dediff erentiation and 
proliferation of podocytes through a 
cAMP / protein kinase A / CREB-dependent 
pathway 1 ( Figure 1 ). Th is pathway requires 
the participation of RAR  in the nucleus 
of podocytes, in addition to the direct acti-
vation of cAMP and protein kinase A in 
the cytoplasm of these cells. Th e mecha-
nism by which retinoic acid receptor ago-
nists induce a direct activation of cAMP 
in the cytoplasm is not well understood, 
but similar findings have been docu-
mented in acute myeloblastic leukemia 
cells. 1 However, Am580 did not prevent 
the progression of HIVAN in dual HIV-
Tg / RAR  knockout mice, 2 suggesting that 
the nuclear RAR  plays a key role in this 
process. Th us, more studies are needed to 
determine how RAR  may induce the 
rapid activation of cAMP in the cyto-
plasm, and to validate this pathway in 
normal human podocytes. Finally, Zhong 
 et al. 1 conclude that the benefi cial eff ects 
of rofl umilast and Am580 were independ-
ent of HIV viral genes. Overall, these 
provocative fi ndings raise several interest-
ing issues that need to be discussed. 
 First, Zhong  et al. 1 used a new colony of 
HIV-Tg mice that was re-derived from the 
parent HIV-Tg 26 mouse line. Th erefore, to 
understand how HIVAN can be cured in 
these mice, it is necessary to review the 
natural history of renal disease in Tg 26 
mice. Briefl y, these mice carry a replication-
defi cient   gag / pol PNL4-3 HIV proviral 
genomic DNA driven by the endogenous 
HIV-1 promoter. 3,4 Th e mRNA expression 
of HIV-1 is detected in a wide range of cells, 
including glomerular and tubular epithelial 
cells. 3 – 5 Viral proteins cannot, however, be 
detected in the circulation or peripheral 
blood mono nuclear cells. Heterozygous 
mice are born with normal kidneys but 
develop progressive renal disease during 
their fi rst months of life. 3,4 Usually, male 
mice develop a more rapid and progressive 
renal disease when compared with female 
mice. 3 – 5 Severe edema and nephrotic 
syndrome occur approximately between 
60 and 250 days of age. 3 – 5 Tg 26 mice 
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usually show blood urea nitrogen (BUN) 
levels exceeding 200  mg / dl and elevated 
serum creatinine (>1  mg / dl) in this time 
period and die of uremia and ascites. 3,4 
However, not all mice develop renal dis-
ease, and others do it in an asynchronous 
and unpredictable manner. 3 – 5 Thus, a 
remarkable fi nding of the study of Zhong 
 et al. 1 is that all untreated control HIV-Tg 
mice, both males and females, developed 
chronic renal failure in a synchronized 
manner during the first 9 weeks of 
life. Moreover, the prevalence of the renal 
disease in the control group was increased 
relative to that in the parent Tg 26 mouse 
line, 3,4 and to the expected prevalence 
( ~ 80 % ) in the re-derived mouse colony. 
We should consider that Zhong  et al. 1 
preselected mice at 4 weeks of age on the 
basis of urine dipstick protein values of 
1  +  / 2  +  (30 – 100  mg / dl). However, similar 
levels of proteinuria can be detected in Tg 26 
mice without renal disease, 3 due to the nor-
mal excretion of low-molecular weight 
tubular proteins and pheromones. In sum-
mary, one limitation of the study by Zhong 
 et al. 1 is that we do not know how many 
mice in each group had preexisting renal 
disease at the beginning of the study. 
 Another limitation of this study is the 
defi nition of chronic renal failure: BUN 
levels greater than 30  mg / dl. Previous 
publications on Tg 26 mice reported simi-
lar BUN levels in mice without renal dis-
ease and used cutoff  BUN values above 
45  mg / dl. 3,4 Th ese BUN values revealed a 
much better correlation with the renal 
histological findings associated with 
chronic renal failure, showing all glome r uli 
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 Figure 1  |  A summary of the possible roles that all- trans retinoic acid and the PDE4 inhibitor roflumilast may play to prevent the progression 
of HIV-associated nephropathy in HIV-Tg 26 mice. Zhong  et al. 
1 showed that all- trans retinoic acid plus the cyclic nucleotide phosphodiesterase 4 
(PDE4) inhibitor roflumilast prevented the progression of HIV-associated nephropathy in transgenic (Tg) mice by blocking the dedifferentiation and 
proliferation of podocytes through a cAMP / protein kinase A / CREB-dependent mechanism that is independent of HIV-1 genes (highlighted in red). 
On the basis of the pathogenesis of the renal disease in Tg 26 mice, 
3 – 5 and the known beneficial effects of these drugs in other experimental models 
of renal diseases, 6 – 8 we have highlighted additional pathological pathways (in black) that might be affected as well. AP-1, activator protein-1; 
ATRA, all- trans retinoic acid analogs; cAMP, cyclic adenosine monophosphate; CREB, cAMP responsive element-binding protein; ECM, extracellular 
matrix proteins; FGF-2, fibroblast growth factor-2; FSGS, focal segmental glomerulosclerosis; HIVAN, HIV-associated nephropathy; HSPG, heparan 
sulfate proteoglycans; MAPK-P, phosphorylated mitogen-activated protein kinase / phosphorylated extracellular signal-regulated kinase; 
MCP-1, monocyte chemoattractant protein-1; MEK, mitogen-activated protein kinase / extracellular signal-regulated kinase kinase; MKP-1, mitogen-
activated protein kinase phosphatase-1; NF-  B, nuclear factor-  B; PDE4, cyclic nucleotide phosphodiesterase 4; PKA, protein kinase A; Raf, rapidly 
accelerated fibrosarcoma protein kinase; RAR  , retinoic acid receptor-  ; RARE, retinoid acid responsive element; Ras, rat sarcoma G protein; 
TGF-  , transforming growth factor-  ; VEGF-A, vascular endothelial growth factor-A. 
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with segmental or global glomeruloscle-
rosis in combination with microcystic 
tubular dilatation. 3,4 In contrast, 30 – 40 % 
of the mice treated with rofl umilast or 
Am580 alone were reported as having 
chronic renal failure but showed only 
 ‘ mild ’ glomerular sclerotic changes, 
very few collapsed glomeruli, and mild 
tubulointerstitial injury scores. Th e data 
presented by Zhong  et al. 1 also appear 
to exclude the possibility that these mice 
suff ered weight loss, or prerenal failure 
secondary to drug-induced diarrhea, 
dehydration, severe edema, nephrotic syn-
drome, or ascites. Th us, it is unclear why 
these mice developed chronic renal failure 
with such renal histological and clinical 
fi ndings. Moreover, a previous study by 
the same group showed that a more pro-
longed treatment with Am580 alone was 
capable of preventing the progression of 
HIVAN in Tg 26 mice. 2 Finally, for the pur-
pose of comparing the outcome of the 
renal disease in mice belonging to the 
original Tg 26 line 3,4 versus those used in 
this study, 1 both the renal histological and 
clinical fi ndings at 9 weeks of age appear 
to be more severe in Tg 26 mice. 3 – 5 
 Nevertheless, when the findings of 
Zhong  et al. 1 are considered in the context 
of previous studies, 6 – 8 it is clear that rof-
lumilast and Am580 have the potential to 
improve the outcome of HIVAN acting 
through diff erent mechanisms and renal 
cell types ( Figure 1 ). For example, Zhong 
 et al. 1 began their treatment when mice 
were 4 weeks of age. Renal electron micros-
copy studies done in Tg 26 mice with renal 
disease at this early time point show 
eff acement of foot processes, expansion of 
the mesangial matrix, narrowing of the 
lumen of glomerular capillaries, simpli-
fi cation and atrophy of tubular epithelial 
cells, and thickening of glomerular and 
tubular basement membranes. 3,5 No renal 
epithelial proliferative changes, however, 
are detected at this early stage. 3,5 Th us, in 
addition to the pro-diff erentiation changes 
in podocytes described by Zhong  et al. , 
these drugs have the potential to improve 
the outcome of HIVAN by blocking 
the synthesis and accumulation of renal 
extracellular matrix proteins. Previous 
studies suggest that these changes can be 
mediated by cAMP-dependent and / or 
transforming growth factor-  -dependent 
mechanisms. 8,9 In addition, blocking the 
synthesis of heparan sulfate proteoglycans 
( Figure 1 ) may prevent the renal accumu-
lation of heparin-binding growth factors, 
including vascular endothelial growth 
factor A (VEGF-A) and fi broblast growth 
factor-2 (FGF-2), which can induce 
renal proliferative changes during the late 
stages of HIVAN in Tg 26 mice. 5 Moreover, 
previous studies showed that drugs 
that increase the intracellular levels of 
cAMP can also decrease the mitogenic 
activity of FGF-2 in cultured human 
primary renal epithelial cells by inhibiting 
the mitogen-activated protein kinase 
(MAPK) signaling pathway 10 ( Figure 1 ). 
In summary, it is tempting to speculate 
that retinoids, in combination with PDE4 
inhibitors, may ameliorate the progression 
of HIVAN independently of HIV genes, 
by blocking the dedifferentiation of 
podocytes and the synthesis of extra-
cellular matrix proteins during the early 
stages of the renal disease, and by prevent-
ing the mitogenic activity of heparin-
binding growth factors during the late 
stages of HIVAN. 
 Finally, roflumilast and Am580 have 
powerful systemic eff ects, which could also 
modulate the outcome of HIVAN in 
humans and Tg mice. For example, reti-
noids can decrease the blood pressure of 
mice with renal disease 8 and may improve 
their renal outcome by modulating 
the activity of nitric oxide synthase, endo-
thelin-1, and / or angiotensin II type 1 recep-
tors. 6 Most notably, these drugs have 
powerful anti-infl ammatory activity and 
can aff ect the recruitment of infl ammatory 
cells, as well as the transcription of infl am-
matory genes, acting through activator 
protein-1- or nuclear factor-  B-related 
mechanisms ( Figure 1 ). 6 Rofl umilast also 
inhibits the expression of the cytokine 
monocyte chemoattractant protein-1 and 
the generation of reactive oxygen species. 7 
On the basis of its anti-infl ammatory activ-
ity, roflumilast was approved by the US 
Food and Drug Administration to treat 
fl ares of chronic obstructive pulmonary 
disease. Unfortunately, this drug cannot be 
used in patients with liver disease and has 
known adverse interactions with several 
HIV medications. Alternatively, retinoids 
are being used in clinical trials to treat skin 
lesions and tumors, including AIDS-associ-
ated Kaposi ’ s sarcoma, and in patients with 
minimal-change disease or focal segmental 
glomerulosclerosis. Overall, we hope that 
these studies will provide valuable informa-
tion to assess the clinical value of rofl umi-
last and Am580 in patients with HIVAN. 
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